(Q35539943)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14502100%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

review article

1 reference

title

Beneficial effects of metformin on haemostasis and vascular function in man (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14502100%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

P J Grant

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14502100%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

publication date

1 September 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14502100%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

published in

Diabetes and Metabolism

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14502100%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14502100%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

4 Pt 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14502100%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

6S44-52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14502100%20AND%20SRC:MED&resulttype=core&format=json

WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

19 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

The reaction between bovine brain tissue factor and factors VII and X.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Tissue factor pathway inhibitor and the revised theory of coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Role of contact system activation in hemodialyzer-induced thrombogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Identification of active tissue factor in human coronary atheroma

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Decreased lateral aggregation of a variant recombinant fibrinogen provides insight into the polymerization mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Sol Sherry Lecture in Thrombosis : research on clot stabilization provides clues for improving thrombolytic therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

GPIIb-IIIa: the responsive integrin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Plasminogen Activator Inhibitor Type-1 Synthesis and mRNA Expression in HepG2 Cells Are Regulated by VLDL

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Increased insulin concentrations in nondiabetic offspring of diabetic parents

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Microalbuminuria and markers of the atherosclerotic process: the D.E.S.I.R. study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Metformin revisited: its actions and indications for use.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASE

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Effect of biguanides and atromid on fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Plasma t-PA and PAI-1 Antigen Concentrations in Non-Insulin Dependent Diabetic Patients: Effects of Treatment Modality on Fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Metformin decreases platelet superoxide anion production in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Platelet dysfunction in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

The effects of metformin on cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2803%2972787-6

7 January 2021

10.1016/S1262-3636(03)72787-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14502100%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference